Search results
The STAR trial has shown that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of adverse events but a nonstatistically significant higher risk of noninvasive breast cancer.
- National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen ...
Methods: The NSABP STAR trial was a randomized,...
- National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen ...
21 cze 2006 · In this initial report of the STAR trial, raloxifene and tamoxifen were equivalent in efficacy for lowering the risk of invasive breast cancer. The cumulative incidence rates were 25.1 per 1000 women (raloxifene) vs 24.8 per 1000 (tamoxifen) (P = .83).
20 maj 2015 · Background: NSABP P-2 (STAR) was a randomized, double-blinded trial of tamoxifen vs raloxifene for the reduction of breast cancer incidence. The initial report from 2006 found raloxifene to be as effective as tamoxifen in preventing invasive breast cancer, but with fewer associated toxicities.
Methods: The NSABP STAR trial was a randomized, double-blinded study comparing the use of tamoxifen 20 mg/day to raloxifene 60 mg/day, for a 5-year period, to reduce the risk of developing invasive breast cancer. Eligible postmenopausal women were required to have a 5-year predicted breast cancer risk of 1.66% based on the modified Gail Model.
However, the large Study of Tamoxifen and Raloxifene (STAR) trial, which directly compared tamoxifen with raloxifene, found that tamoxifen reduced breast cancer risk more than raloxifene after long-term follow-up 3 . For women with a predicted 5-year breast cancer risk of 3% or greater, the absolute benefits are likely even higher.
The Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer trial opened in 1999 to directly com-pare raloxifene to tamoxifen for breast cancer risk reduction.
9 lis 2010 · The NSABP Study of Tamoxifen and Raloxifene (STAR) compared raloxifene to tamoxifen for the prevention of breast cancer in postmenopausal women at increased risk for the disease.
